Treats Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism. ANDA 216505, held by Rubicon Research. Carbidopa; Levodopa.
As of Nov 21, 2026, ANDA 216505 (Carbidopa and Levodopa), held by Rubicon Research, was first approved by FDA on Sep 21, 2022, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Carbidopa and levodopa tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 21, 2022 | Original application | Approved | None posted |
| Carbidopa and Levodopa10MG;100MG · tablet;oral | Carbidopa; Levodopa | Rx |
| Carbidopa and Levodopa25MG;100MG · tablet;oral | Carbidopa; Levodopa | Rx |
| Carbidopa and Levodopa25MG;250MG · tablet;oral | Carbidopa; Levodopa | Rx |
| Jun 24, 2026 | Supplement 14Labeling · Standard review | Approved | None posted |
| Sep 21, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters